The Vigabatrin REMS Program is needed by the FDA to make certain educated risk-benefit choices prior to starting treatment, and to make sure appropriate use of vigabatrin while clients are dealt with. It is not feasible for your doctor to understand when vision loss will happen.
It is suggested that your healthcare provider test your (or your child's) vision prior to or within 4 weeks after beginning SABRIL and at least every 3 months during treatment up until SABRIL is stopped. If you or your youngster have any type of side effect that troubles you or that does not go away, tell your medical care service provider.
Inform your healthcare provider if you are pregnant or intend to obtain expecting. If vision screening can not be done, your healthcare provider might continue suggesting SABRIL, but will not be able to expect any kind of vision loss. If vision examinations are not done routinely, your doctor might stop recommending SABRIL for you (or your youngster).